Vaccine prepared from attenuated strain of Ehrlichia canis
|
Categories |
Veterinary Medicine, Veterinary Formulations |
|
Development Stage |
Proof of Concept |
|
Patent Status |
Patent Applications filed in US, Europe and Israel |
|
Market |
Canine ehrlichiosis occurs over most of the range of the common brown dog tick (Rhipicephalus sanguineus), in Africa, the Middle East, east Asia, South East Asia, South America, the Caribbean and the USA (southern states and Hawaii). There is no vaccine currently available. |
Highlights
-
Vaccine for the prevention of ehrlichiosis in dogs and other canine species
-
Bacterial tick-borne disease affects dogs and other canines throughout the United States and worldwide
-
Initial effect seen in small sampleChallenged Dogs did not developed clinical signs
Our Innovation
Attenuated strain of E. canis prepared through serial passage in tissue culture is used to prepare a vaccine that effectively prevents ehrlichiosis in canines
Ehrlichiosis attenuated Strain
Key Features
-
Induces protective immunity against clinical manifestation of the disease
-
Proprietary strain of Ehrlichia canis
-
Low bacterial load post challenge in the vaccinated dogs
Development Milestones
-
Looking for commercial partners for further development and commercialisation purposes
The Opportunity
-
Ehrlichiosis is one of the most common infectious diseases in canines
-
Found in pet dogs as well as foxes, wolves, jackals and other wild canines
Link to Article
www.yissum.co.il/sites/default/files/project_images/Articles/1839_harrus__baneth_2012_vaccine.pdf
1586128900.png)